Brigatinib versus crizotinib in patients with ALK inhibitor–naive advanced ALK+ NSCLC: results from the phase 3 ALTA-1L trial. (January 2020) - Califano, R.; Camidge, D.; Kim, H.-R.; Ahn, M.-J.; Yang, J.; Han, J.-Y.; Hochmair, M.; Lee, K.H.; Delmonte, A.; Campelo, M.R. Garcia; Kim, D.-W.; Griesinger, F.; et al.